JP2018522045A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522045A5 JP2018522045A5 JP2018505665A JP2018505665A JP2018522045A5 JP 2018522045 A5 JP2018522045 A5 JP 2018522045A5 JP 2018505665 A JP2018505665 A JP 2018505665A JP 2018505665 A JP2018505665 A JP 2018505665A JP 2018522045 A5 JP2018522045 A5 JP 2018522045A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- ezh2 inhibitor
- tumor
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 61
- 201000011510 cancer Diseases 0.000 claims description 52
- 239000003112 inhibitor Substances 0.000 claims description 45
- 238000000034 method Methods 0.000 claims description 39
- 210000002865 immune cell Anatomy 0.000 claims description 21
- 210000000822 natural killer cell Anatomy 0.000 claims description 20
- 230000001629 suppression Effects 0.000 claims description 19
- 210000004981 tumor-associated macrophage Anatomy 0.000 claims description 19
- 239000002955 immunomodulating agent Substances 0.000 claims description 15
- 230000002584 immunomodulator Effects 0.000 claims description 14
- 229940121354 immunomodulator Drugs 0.000 claims description 14
- 230000002401 inhibitory effect Effects 0.000 claims description 13
- 210000004027 cell Anatomy 0.000 claims description 12
- 230000001404 mediated effect Effects 0.000 claims description 10
- 230000006052 T cell proliferation Effects 0.000 claims description 9
- 229960002621 pembrolizumab Drugs 0.000 claims description 8
- 210000003289 regulatory T cell Anatomy 0.000 claims description 8
- 230000005746 immune checkpoint blockade Effects 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 208000017604 Hodgkin disease Diseases 0.000 claims description 4
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 4
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 4
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 229960003852 atezolizumab Drugs 0.000 claims description 4
- 229950009791 durvalumab Drugs 0.000 claims description 4
- 229960005386 ipilimumab Drugs 0.000 claims description 4
- NSQSAUGJQHDYNO-UHFFFAOYSA-N n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzamide Chemical group C=1C(C=2C=CC(CN3CCOCC3)=CC=2)=CC(C(=O)NCC=2C(NC(C)=CC=2C)=O)=C(C)C=1N(CC)C1CCOCC1 NSQSAUGJQHDYNO-UHFFFAOYSA-N 0.000 claims description 4
- 229960003301 nivolumab Drugs 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 238000011275 oncology therapy Methods 0.000 claims description 3
- 229950010773 pidilizumab Drugs 0.000 claims description 3
- FKSFKBQGSFSOSM-QFIPXVFZSA-N 1-[(2S)-butan-2-yl]-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3-methyl-6-[6-(1-piperazinyl)-3-pyridinyl]-4-indolecarboxamide Chemical compound C1=C2N([C@@H](C)CC)C=C(C)C2=C(C(=O)NCC=2C(NC(C)=CC=2C)=O)C=C1C(C=N1)=CC=C1N1CCNCC1 FKSFKBQGSFSOSM-QFIPXVFZSA-N 0.000 claims description 2
- ZOIBZSZLMJDVDQ-UHFFFAOYSA-N 1-cyclopentyl-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-6-[4-(4-morpholinylmethyl)phenyl]-4-indazolecarboxamide Chemical compound O=C1NC(C)=CC(C)=C1CNC(=O)C1=CC(C=2C=CC(CN3CCOCC3)=CC=2)=CC2=C1C=NN2C1CCCC1 ZOIBZSZLMJDVDQ-UHFFFAOYSA-N 0.000 claims description 2
- OMKHWTRUYNAGFG-IEBDPFPHSA-N 3-deazaneplanocin a Chemical compound C1=NC=2C(N)=NC=CC=2N1[C@@H]1C=C(CO)[C@@H](O)[C@H]1O OMKHWTRUYNAGFG-IEBDPFPHSA-N 0.000 claims description 2
- PFHDWRIVDDIFRP-UHFFFAOYSA-N 6-cyano-n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-1-pentan-3-ylindole-4-carboxamide Chemical compound C1=C(C#N)C=C2N(C(CC)CC)C=CC2=C1C(=O)NCC1=C(C)C=C(C)NC1=O PFHDWRIVDDIFRP-UHFFFAOYSA-N 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- ULNXAWLQFZMIHX-UHFFFAOYSA-N GSK343 Chemical compound C1=C(C)NC(=O)C(CNC(=O)C=2C=3C=NN(C=3C=C(C=2)C=2C=C(N=CC=2)N2CCN(C)CC2)C(C)C)=C1CCC ULNXAWLQFZMIHX-UHFFFAOYSA-N 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 201000005969 Uveal melanoma Diseases 0.000 claims description 2
- 229950002916 avelumab Drugs 0.000 claims description 2
- 238000001574 biopsy Methods 0.000 claims description 2
- 230000000903 blocking effect Effects 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 230000002503 metabolic effect Effects 0.000 claims description 2
- XQFINGFCBFHOPE-UHFFFAOYSA-N n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-3-[ethyl-[4-[2-methoxyethyl(methyl)amino]cyclohexyl]amino]-2-methyl-5-(3-morpholin-4-ylprop-1-ynyl)benzamide Chemical compound C=1C(C#CCN2CCOCC2)=CC(C(=O)NCC=2C(NC(C)=CC=2C)=O)=C(C)C=1N(CC)C1CCC(N(C)CCOC)CC1 XQFINGFCBFHOPE-UHFFFAOYSA-N 0.000 claims description 2
- DPJNKUOXBZSZAI-UHFFFAOYSA-N n-[(6-methyl-2-oxo-4-propyl-1h-pyridin-3-yl)methyl]-1-propan-2-yl-6-[6-(4-propan-2-ylpiperazin-1-yl)pyridin-3-yl]indazole-4-carboxamide Chemical compound C1=C(C)NC(=O)C(CNC(=O)C=2C=3C=NN(C=3C=C(C=2)C=2C=NC(=CC=2)N2CCN(CC2)C(C)C)C(C)C)=C1CCC DPJNKUOXBZSZAI-UHFFFAOYSA-N 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 26
- 102000058017 Enhancer of Zeste Homolog 2 Human genes 0.000 claims 22
- 101710196274 Histone-lysine N-methyltransferase EZH2 Proteins 0.000 claims 22
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 208000007569 Giant Cell Tumors Diseases 0.000 claims 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 230000012177 negative regulation of immune response Effects 0.000 claims 1
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 description 17
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 description 17
- 210000002540 macrophage Anatomy 0.000 description 3
- 0 C[C@]([C@]1CC(*)N(C)CC1)[n]1c(cccc2)c2c(C(NCC(C(NC(C)=C2)=O)=C2OC)=O)c1C Chemical compound C[C@]([C@]1CC(*)N(C)CC1)[n]1c(cccc2)c2c(C(NCC(C(NC(C)=C2)=O)=C2OC)=O)c1C 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562200244P | 2015-08-03 | 2015-08-03 | |
| US62/200,244 | 2015-08-03 | ||
| PCT/US2016/044409 WO2017023671A1 (en) | 2015-08-03 | 2016-07-28 | Ezh2 inhibitors and modulation of regulatory t-cell function |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018522045A JP2018522045A (ja) | 2018-08-09 |
| JP2018522045A5 true JP2018522045A5 (enExample) | 2019-09-12 |
Family
ID=56611618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018505665A Pending JP2018522045A (ja) | 2015-08-03 | 2016-07-28 | Ｅｚｈ２阻害剤および制御性ｔ細胞機能の調節 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20180221362A1 (enExample) |
| EP (1) | EP3331561A1 (enExample) |
| JP (1) | JP2018522045A (enExample) |
| CN (1) | CN108136011A (enExample) |
| AU (1) | AU2016302747A1 (enExample) |
| CA (1) | CA2994394A1 (enExample) |
| HK (1) | HK1256604A1 (enExample) |
| WO (1) | WO2017023671A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017273726B2 (en) * | 2016-06-01 | 2023-10-19 | Epizyme, Inc. | Use of EZH2 inhibitors for treating cancer |
| AU2018275123A1 (en) * | 2017-06-02 | 2020-01-30 | Epizyme, Inc. | Use of EZH2 inhibitors for treating cancer |
| CN120097995A (zh) | 2018-05-21 | 2025-06-06 | 星座制药公司 | 甲基修饰酶的调节剂、其组合物和用途 |
| WO2019241742A1 (en) * | 2018-06-14 | 2019-12-19 | Board Of Regents, The University Of Texas System | Combination of ezh2 inhibitor and checkpoint therapy for the treatment of cancer |
| WO2020063863A1 (zh) * | 2018-09-29 | 2020-04-02 | 江苏恒瑞医药股份有限公司 | Ezh2抑制剂与免疫检查点抑制剂联合在制备治疗肿瘤的药物中的用途 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| TW202028222A (zh) * | 2018-11-14 | 2020-08-01 | 美商Ionis製藥公司 | Foxp3表現之調節劑 |
| CN112007162B (zh) * | 2019-05-30 | 2023-05-12 | 江苏恒瑞医药股份有限公司 | Ezh2抑制剂与免疫检查点抑制剂、vegfr抑制剂联合在制备治疗肿瘤药物中的用途 |
| CN114040776B (zh) * | 2019-06-28 | 2024-05-14 | 江苏恒瑞医药股份有限公司 | Tlr激动剂与抗ox40抗体或其抗原结合片段联合在制备治疗肿瘤的药物中的用途 |
| BR112022001154A2 (pt) * | 2019-07-24 | 2022-06-07 | Constellation Pharmaceuticals Inc | Terapias de inibição de ezh2 para o tratamento de cânceres |
| CN114555112A (zh) | 2019-08-22 | 2022-05-27 | 朱诺治疗学股份有限公司 | T细胞疗法和zeste增强子同源物2(ezh2)抑制剂的组合疗法及相关方法 |
| WO2023108563A1 (zh) * | 2021-12-16 | 2023-06-22 | 北京大学第三医院（北京大学第三临床医学院） | 包含ezh2抑制剂和scd1抑制剂的抗肿瘤药物组合物及其用途 |
| KR20240072936A (ko) * | 2022-11-17 | 2024-05-24 | 인제대학교 산학협력단 | Ezh2 저해제 및 항-pd-1 항체를 포함하는, 암의 예방 또는 치료용 약제학적 조성물 |
| WO2025085536A1 (en) * | 2023-10-16 | 2025-04-24 | Lankenau Institute For Medical Research | Biologic conjugates that inhibit production of inflammatory cells and methods of use |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2170959T1 (sl) * | 2007-06-18 | 2014-04-30 | Merck Sharp & Dohme B.V. | Protitelesa proti receptorjem pd-1 za humano programirano smrt |
| ES2528269T3 (es) * | 2010-05-07 | 2015-02-06 | Glaxosmithkline Llc | Azaindazoles |
| AU2011298987B2 (en) * | 2010-09-10 | 2017-09-28 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| CA2854447A1 (en) * | 2011-11-04 | 2013-05-10 | Glaxosmithkline Intellectual Property (No.2) Limited | Method of treatment |
| EP2780014A4 (en) | 2011-11-18 | 2015-07-01 | Constellation Pharmaceuticals Inc | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF |
| EP2780013A4 (en) | 2011-11-18 | 2015-07-01 | Constellation Pharmaceuticals Inc | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF |
| WO2013078320A1 (en) | 2011-11-21 | 2013-05-30 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| NZ628762A (en) | 2012-02-10 | 2016-07-29 | Constellation Pharmaceuticals Inc | Modulators of methyl modifying enzymes, compositions and uses thereof |
| CN103690531A (zh) * | 2012-09-27 | 2014-04-02 | 烟台大学 | 茶乙香酸等在制备具有预防和治疗癌症等疾病的产品中的应用 |
| MA38341B1 (fr) * | 2013-02-11 | 2018-11-30 | Constellation Pharmaceuticals Inc | Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées |
| EP2970305B1 (en) | 2013-03-15 | 2017-02-22 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| EP3033334A1 (en) | 2013-08-15 | 2016-06-22 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
-
2016
- 2016-07-28 WO PCT/US2016/044409 patent/WO2017023671A1/en not_active Ceased
- 2016-07-28 HK HK18115733.0A patent/HK1256604A1/zh unknown
- 2016-07-28 JP JP2018505665A patent/JP2018522045A/ja active Pending
- 2016-07-28 US US15/749,890 patent/US20180221362A1/en not_active Abandoned
- 2016-07-28 CA CA2994394A patent/CA2994394A1/en not_active Abandoned
- 2016-07-28 CN CN201680057570.1A patent/CN108136011A/zh active Pending
- 2016-07-28 EP EP16748243.9A patent/EP3331561A1/en not_active Withdrawn
- 2016-07-28 AU AU2016302747A patent/AU2016302747A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018522045A5 (enExample) | ||
| Purcell et al. | LRRC15 is a novel mesenchymal protein and stromal target for antibody–drug conjugates | |
| Zang et al. | Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy | |
| JP2016539134A5 (enExample) | ||
| JP2017530950A5 (enExample) | ||
| EA202090955A1 (ru) | Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови | |
| WO2010063011A3 (en) | Methods for the treatment of infections and tumors | |
| EP4371562A3 (en) | 2-quinolone derived inhibitors of bcl6 | |
| JP2016536286A5 (enExample) | ||
| MX380928B (es) | Inhibidores de kras g12c. | |
| EP4241850A3 (en) | Mdm2 inhibitors and combinations thereof | |
| JP2018522858A5 (enExample) | ||
| UA118233C2 (uk) | Сполуки, які інгібують білок mcl-1 | |
| JP2015533176A5 (enExample) | ||
| MX379459B (es) | Inhibidores de bromodominios. | |
| JP2017537070A5 (enExample) | ||
| MX2021011563A (es) | Derivados de 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmaceuticas que los incluyen. | |
| WO2013112950A3 (en) | Certain chemical entities, compositions, and methods | |
| WO2015095834A3 (en) | Cancer treatments using erk1/2 and bcl-2 family inhibitors | |
| KR20230167407A (ko) | Cbl-b 억제제 화합물을 이용한 조합 요법 | |
| RU2015132370A (ru) | Химические соединения | |
| RU2020109376A (ru) | Применение антагонистов рецептора ep4 для лечения nash- ассоциированного рака печени | |
| AU2019362050B2 (en) | Combinations for immune-modulation in cancer treatment | |
| WO2014106800A8 (en) | Substituted 2-amino pyrimidine derivatives as kinase inhibitors | |
| MX2015000746A (es) | Terapia de combinacion de inhibidores para el receptor del factor de crecimiento insulinico tipo 1 (igf1r) y fosfatidilinositol 3-cinasa (pi3k). |